A Study Comparing Chemotherapy to CPX-351 and/or Gilteritinib for Acute Myeloid Leukemia
Phase 3
1,186
about 8.9 years
≤21
185 sites in AL, AR, AZ +44
About this study
Researchers are testing whether a treatment with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib, in addition to standard chemotherapy, improves outcomes for people newly diagnosed with acute myeloid leukemia. The trial will compare the effects of this new treatment approach to standard chemotherapy alone.
Based on ClinicalTrials.gov records.
What participants do
- 1.Fludeoxyglucose F-18
- 2.Questionnaire Administration
- 3.Take Asparaginase Erwinia chrysanthemi
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS, cytarabine, Antineoplastic Agent [TC] (DNA Polymerase Inhibitors), Cardiovascular Agent [TC] (Chelating Activity), etoposide, fludeoxyglucose (18F), gemtuzumab ozogamicin, Antineoplastic Agent [TC] (Receptor Tyrosine Kinase Inhibitors)
injection (Injection), infusion, injection, intravenous, oral (Oral Tablet)
Primary: Event-free survival (EFS)
Secondary: Incidence of adverse events, Overall survival (OS)
diagnostic, biopsy, imaging
Oncology